Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01331018 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy for Fanconi Anemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01331018 is a Phase 1 study that was terminated before completion, run by Fred Hutchinson Cancer Center. The registered enrollment target is 3 participants.
The verdict
NCT01331018, a Phase 1 study, was terminated before completion, sponsored by Fred Hutchinson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This clinical trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with FA.
Interventions
- PROCEDURE Bone Marrow Aspiration
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Filgrastim
- PROCEDURE Leukapheresis
- BIOLOGICAL Genetically Engineered Hematopoietic Stem Progenitor Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2012-02-22 |
| Est. Completion | 2024-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01331018
The ClinicalTrials.gov registry entry for NCT01331018 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bone Marrow Aspiration is the first listed.
NCT01331018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01331018 about?
NCT01331018 is a clinical study titled "Gene Therapy for Fanconi Anemia". This clinical trial will access the toxicity and efficacy of infusion of gene modified cells for patients with Fanconi anemia (FA). Infusion of autologous patient blood stem cells that have been corrected in the laboratory by introduction of the normal gene may improve blood counts in patients with ...
What is the current status of trial NCT01331018?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2012-02-22. Estimated completion is 2024-02-15.
What interventions are being tested in trial NCT01331018?
The interventions under investigation include: Bone Marrow Aspiration (PROCEDURE), Laboratory Biomarker Analysis (OTHER), Filgrastim (BIOLOGICAL), Leukapheresis (PROCEDURE), Genetically Engineered Hematopoietic Stem Progenitor Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01331018?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.